Navigation Links
Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
Date:5/27/2008

BURLINGAME, Calif., May 27 /PRNewswire/ -- Epitomics, Inc., the rabbit monoclonal antibody company, announced today that it has developed its 1000th new rabbit monoclonal antibody. Each antibody has been created, tested and QC'd in house utilizing Epitomics' proprietary rabbit monoclonal antibody technology. "We are very excited to have reached this milestone in a short period of time. This demonstrated the robustness of our technology and development pipeline," said Dr. Guo-Liang Yu, President and CEO of Epitomics Inc. "While thousands of antibodies exist in the market our Rabbit Monoclonal antibody technology has allowed for the development of monoclonal antibodies that were previously only possible to develop as a polyclonal antibody if at all," said Dr. Yu, "many of the targets for which we have developed a Rabbit Monoclonal, no other monoclonal antibody had existed previously."

Epitomics is the exclusive provider of a proprietary method for making monoclonal antibodies from rabbits rather the conventional method of starting with mice. The advantages of Epitomics' rabbit monoclonal antibodies (RabMAbs(TM)) include high specificity and affinity which provide excellent results in a variety of commonly used immunoassays. "Each one of our rabbit monoclonal antibodies undergoes stringent testing in five major immunoassays including Western blotting, Immunohistochemistry, Immunofluorescence, Immunopreciptation and Flow Cytometry, before being released," said Dr. Peter Li, Senior VP of Product Development, "our rabbit monoclonals are among the most extensively characterized antibodies available." The complete list of Rabbit Monoclonals including background information and data for each antibody is available for viewing on Epitomics website.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb(TM) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. The Company is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. More information about Epitomics can be found at http://www.epitomics.com


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NicOx Announces Departure of Damian Marron for CEO Position
2. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
3. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
4. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
5. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
6. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
7. Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System
8. Amarin Announces Completion of the First Tranche of $60 Million Private Placement
9. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
10. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
11. Biopure Announces 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
(Date:6/22/2016)... --  ViaCyte, Inc. , a privately-held regenerative medicine company ... for the treatment of diabetes in clinical-stage development, today ... 2016, the Global Stem Cell Event, is taking place ... Francisco.    ... Focus Session: Tools for Basic and Applied Stem Cell ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):